The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
24-Dec-24
Undisclosed
Target:
Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)
Acquiror:
Neuraxpharm Group
Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)
17-Dec-24
$962 million
Target:
Renewable assets in Chile involving hybrid solar power generation and storage
Acquiror:
Contour Global
Advised ContourGlobal (KKR) in the acquisition of 3 independent solar (Quillagua I & II, and Victor Jara) and BESS projects from Grenergy
12-Dec-24
$460 million
Target:
Brigit
Acquiror:
Upbound Group
Advised Upbound Group, a technology and data-driven leader in accessible and inclusive financial products that address the evolving needs and aspirations of underserved consumers, on its acquisition of Brigit, a leading financial health technology company
04-Dec-24
$542 million (CAD value)
Target:
Heartland Generation
Acquiror:
TransAlta Corporation
Strategic advisor to Heartland Generation, one of Alberta's largest power generators and an Energy Capital Partners affiliate, on its sale to TransAlta Corporation
27-Nov-24
$618 million
Target:
Empire Today
Advised Empire Today, the largest and only national DTC provider of replacement hard surface flooring and carpet in the U.S., on its liability management transaction